Also known as:Tirz· community shorthandMounjaro· brand nameZepbound· brand nameLY3298176· development code
Type 2 diabetesobesity
Tirzepatide
Evidence levelLate-stage human
Human evidenceSubstantial
Regulatory statusAuthorised products exist
What you need to know in 20 seconds
What is it?
GIP/GLP-1 receptor agonist peptide
Research focus
Type 2 diabetes, obesity, weight management
Human evidence
Large Phase III obesity evidence shows substantial weight loss. SURMOUNT-OSA additionally demonstrated large reductions in sleep-apnea severity in adults with obesity and moderate-to-severe OSA.
Regulatory status
Tirzepatide is authorised in licensed products such as Mounjaro for type 2 diabetes and adult weight management in the EU; authorization is product- and jurisdiction-specific.
Main limitations
Safety/quality of unverified products and uses outside authorised indications are not established.
Safety
GI adverse effects are common; hypoglycaemia risk rises with some diabetes drugs; product labels contain additional warnings.
i
Large Phase III obesity evidence shows substantial weight loss. SURMOUNT-OSA additionally demonstrated large reductions in sleep-apnea severity in adults with obesity and moderate-to-severe OSA.
What the evidence actually supports
✓High-quality human outcome evidence; present approved-product status separately by jurisdiction/indication.
✓Adds a second major clinical outcome beyond weight loss.
What is not established / key limitations
×GI adverse effects and treatment discontinuation occurred; results do not imply equivalent safety/quality of non-authorized products.
×Does not establish benefit for non-obesity-related sleep apnea.
2024 · Two randomized double-blind placebo-controlled trials · n=469
AHI treatment differences versus placebo were about -20.0 events/hour in trial 1 and -23.8 events/hour in trial 2; secondary sleep/cardiometabolic measures also improved.
GI adverse effects are common; hypoglycaemia risk rises with some diabetes drugs; product labels contain additional warnings.
Gastrointestinal adverse effects are common; labelled warnings/contraindications, titration and approved formulation matter.
Technical details
Mechanism / biologyDual agonism at GIP and GLP-1 receptors improves glucose-dependent insulin signalling and reduces food intake.
Route / formulation boundaryUnverified research-market material or non-authorised pens are not equivalent to licensed tirzepatide medicines merely because the active-ingredient name matches.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusVerified dosing evidence added. UK licensed dosing example. See dosing_evidence records for route, regimen, population, duration and source.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
